Medical Equipment/Supplies/Accessories · Founded 1988 · www.pacetronix.com · BSE 527005 · · ISIN INE847D01010
No Notes Added Yet
Business
Shree Pacetronix Ltd. is an Indian company operating in the Medical Equipment/Supplies/Accessories sector. Given its name "Pacetronix," it is highly probable that the company is involved in the manufacturing, distribution, and/or sale of medical electronic devices, possibly with a focus on cardiac care devices like pacemakers or related monitoring equipment, or a broader range of medical technology products. Its core business model would involve developing or sourcing medical devices, obtaining necessary regulatory approvals, and then selling these products to hospitals, clinics, healthcare providers, and potentially directly to patients or through a network of distributors. The company generates revenue through the sale of these medical devices and associated accessories or services.
Revenue Mix
Specific details regarding Shree Pacetronix Ltd.'s key business segments or revenue mix are not publicly available based on the provided information. However, within the Medical Equipment sector, potential segments could include diagnostic equipment, therapeutic devices (e.g., cardiac devices, surgical instruments), medical consumables, or services related to equipment installation and maintenance. Without further data, a precise breakdown is not possible.
Industry
The Indian medical equipment market is a rapidly growing industry, driven by increasing healthcare expenditure, a rising burden of chronic diseases, and improving healthcare infrastructure. The market is characterized by a mix of large multinational corporations (MNCs) and a growing number of domestic manufacturers. MNCs often dominate high-tech and specialized segments, while local players, like potentially Shree Pacetronix Ltd., often compete on factors like cost-effectiveness, regional distribution, and understanding of local market needs. The company's exact positioning would depend on its product portfolio (e.g., niche vs. broad), market share in specific product categories, and distribution network strength compared to both domestic and international peers.
MOAT
Without specific operational details, identifying a durable competitive advantage for Shree Pacetronix Ltd. is speculative. Potential moats in the medical equipment sector could include:
Regulatory Expertise: Strong ability to navigate India's complex regulatory landscape for medical devices.
Specialized Product Knowledge/Technology: Proprietary technology or deep expertise in a specific niche (e.g., pacemaker components).
Distribution Network: An established and efficient sales and service network across India.
Cost Efficiency: Ability to manufacture or source products at a lower cost than competitors, offering competitive pricing.
Brand Reputation: A trusted brand among healthcare professionals for reliability and quality.
Growth Drivers
Rising Healthcare Expenditure: Increasing public and private spending on healthcare in India.
Growing Disease Prevalence: An aging population and increasing incidence of non-communicable diseases (e.g., cardiovascular diseases) driving demand for medical devices.
Infrastructure Development: Expansion of hospitals, clinics, and diagnostic centers across urban and semi-urban areas.
Technological Advancement: Continuous innovation in medical technology creating new product opportunities and upgrading cycles.
Government Initiatives: "Make in India" campaigns and other policies promoting domestic manufacturing and affordable healthcare.
Risks
Intense Competition: Facing competition from both established global players and other domestic manufacturers.
Regulatory Changes: Evolving and stringent regulations for medical devices in India could impact product development, approval, and market access.
Technological Obsolescence: Rapid advancements in medical technology could render existing products outdated.
Pricing Pressure: Pressure from healthcare providers and government procurement policies to offer competitive pricing.
Supply Chain Disruptions: Dependence on raw materials or components which could be subject to global supply chain vulnerabilities.
Economic Downturns: Reduced healthcare spending by individuals and institutions during economic slowdowns.
Management & Ownership
Specific details about the promoters, key management personnel, or ownership structure of Shree Pacetronix Ltd. are not provided. In many Indian companies, a promoter group typically holds a significant stake and plays a crucial role in strategic decision-making. The quality of management would depend on their experience in the medical device sector, track record of innovation, regulatory compliance, and market execution.
Outlook
Shree Pacetronix Ltd. operates within an attractive and growing sector in India. The increasing demand for healthcare services and medical devices presents significant tailwinds for the company. Its ability to capitalize on these opportunities will depend on its product innovation, regulatory compliance, efficient manufacturing or sourcing, and robust distribution capabilities. The company will likely face ongoing challenges from intense competition, particularly from global players, and the need to adapt to evolving technological standards and regulatory frameworks. Success hinges on its strategic focus within the medical equipment landscape and its ability to carve out or expand its niche effectively.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 7 | 5 | 4 | 4 | 4 | 5 | 7 | 4 | 5 | 5 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 7 | 5 | 4 | 4 | 4 | 5 | 7 | 4 | 5 | 5 |
| Total Expenditure | 4 | 4 | 4 | 3 | 3 | 4 | 5 | 4 | 4 | 4 |
| Operating Profit | 2 | 1 | 0 | 0 | 1 | 1 | 2 | 0 | 2 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 2 | 1 | 0 | -0 | 1 | 1 | 2 | 0 | 1 | 1 |
| Provision for Tax | 1 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 1 | 0 | 0 | -0 | 0 | 1 | 1 | 0 | 1 | 1 |
| Adjustments | 0 | 0 | 0 | -0 | -0 | 0 | -0 | 0 | 0 | 0 |
| Profit After Adjustments | 1 | 0 | 0 | -0 | 0 | 1 | 1 | 0 | 1 | 1 |
| Adjusted Earnings Per Share | 4 | 1 | 0.1 | -0.3 | 1.3 | 1.8 | 3.6 | 0.2 | 3 | 2 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 7 | 7 | 7 | 7 | 7 | 9 | 8 | 9 | 20 | 22 | 17 | 21 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 7 | 7 | 7 | 7 | 7 | 9 | 8 | 9 | 20 | 22 | 17 | 21 |
| Total Expenditure | 6 | 6 | 6 | 6 | 6 | 8 | 7 | 7 | 15 | 16 | 14 | 17 |
| Operating Profit | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 6 | 6 | 2 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Depreciation | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -0 | -0 | -0 | 0 | 0 | 0 | 0 | 1 | 5 | 5 | 1 | 4 |
| Provision for Tax | -0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Profit After Tax | -0 | -0 | -0 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 1 | 3 |
| Adjustments | 0 | 0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 |
| Profit After Adjustments | -0 | -0 | -0 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 1 | 3 |
| Adjusted Earnings Per Share | -0.2 | -0.2 | -0.9 | 0.4 | 0.4 | 0.7 | 0.1 | 2.2 | 9.1 | 9.3 | 2.1 | 8.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -23% | 24% | 14% | 9% |
| Operating Profit CAGR | -67% | 0% | 15% | 7% |
| PAT CAGR | -67% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -29% | -25% | 65% | 31% |
| ROE Average | 6% | 25% | 18% | 8% |
| ROCE Average | 9% | 30% | 22% | 13% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 10 | 13 | 14 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 |
| Other Non-Current Liabilities | 0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Total Current Liabilities | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 5 | 6 | 8 | 9 |
| Total Liabilities | 9 | 9 | 9 | 9 | 10 | 11 | 11 | 12 | 16 | 21 | 23 |
| Fixed Assets | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 |
| Other Non-Current Assets | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Total Current Assets | 6 | 6 | 6 | 6 | 7 | 6 | 6 | 7 | 11 | 15 | 17 |
| Total Assets | 9 | 9 | 9 | 9 | 10 | 11 | 11 | 12 | 16 | 21 | 23 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 |
| Cash Flow from Operating Activities | 0 | 1 | 0 | 1 | 0 | 2 | 1 | 2 | 2 | -0 | -0 |
| Cash Flow from Investing Activities | -0 | -0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -2 | -0 |
| Cash Flow from Financing Activities | 0 | -1 | 0 | -1 | 0 | -1 | -0 | -0 | -1 | 2 | 0 |
| Net Cash Inflow / Outflow | 0 | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -0.17 | -0.24 | -0.9 | 0.37 | 0.39 | 0.66 | 0.15 | 2.17 | 9.06 | 9.33 | 2.08 |
| CEPS(Rs) | 1.94 | 1.89 | 0.91 | 1.54 | 1.44 | 2.07 | 1.56 | 3.55 | 10.8 | 11.98 | 4.33 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 14.91 | 14.68 | 13.77 | 14.45 | 14.84 | 15.5 | 15.65 | 17.82 | 26.88 | 36.21 | 38.29 |
| Core EBITDA Margin(%) | 14.89 | 14.42 | 7.83 | 13.57 | 10.78 | 13.59 | 12.43 | 19.27 | 26.9 | 26.54 | 13.91 |
| EBIT Margin(%) | 4.37 | 4.32 | -0.69 | 7.56 | 7.92 | 8.34 | 6.41 | 14.67 | 24.27 | 23.02 | 9.83 |
| Pre Tax Margin(%) | -1.77 | -0.64 | -6.45 | 2.79 | 3.49 | 4.03 | 1.74 | 11.49 | 22.81 | 20.97 | 6.21 |
| PAT Margin (%) | -0.87 | -1.15 | -4.68 | 1.95 | 1.94 | 2.71 | 0.7 | 8.46 | 16.09 | 15.24 | 4.46 |
| Cash Profit Margin (%) | 10.13 | 9.16 | 4.7 | 8.16 | 7.11 | 8.49 | 7.44 | 13.85 | 19.2 | 19.56 | 9.27 |
| ROA(%) | -0.67 | -0.97 | -3.79 | 1.48 | 1.43 | 2.23 | 0.49 | 6.9 | 23.18 | 17.89 | 3.42 |
| ROE(%) | -1.11 | -1.61 | -6.34 | 2.61 | 2.68 | 4.34 | 0.95 | 12.96 | 40.52 | 29.58 | 5.59 |
| ROCE(%) | 3.82 | 4.18 | -0.64 | 6.51 | 6.63 | 8.05 | 5.46 | 14.81 | 46.13 | 34.76 | 9.13 |
| Receivable days | 85.62 | 77.05 | 104.03 | 129.34 | 143.39 | 130.66 | 150.75 | 123.63 | 71.58 | 77.58 | 122.59 |
| Inventory Days | 161.2 | 139.52 | 134.26 | 129.54 | 114.5 | 89.76 | 95.42 | 71.51 | 41.86 | 72.27 | 138.71 |
| Payable days | 48.16 | 25.87 | 30.02 | 37.91 | 40.73 | 43.87 | 58.67 | 29.31 | 20.22 | 21.44 | 36.89 |
| PER(x) | 0 | 0 | 0 | 0 | 32.77 | 0 | 78.44 | 9.38 | 10.78 | 16.27 | 29.91 |
| Price/Book(x) | 0 | 1.06 | 0.71 | 0 | 0.87 | 0 | 0.74 | 1.14 | 3.63 | 4.19 | 1.63 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.88 | 0.97 | 0.88 | 0.85 | 1.11 | 0.73 | 0.87 | 0.97 | 1.8 | 2.64 | 1.57 |
| EV/Core EBITDA(x) | 5.73 | 6.65 | 10.17 | 6.13 | 8.49 | 5.17 | 6.63 | 4.83 | 6.58 | 9.64 | 10.73 |
| Net Sales Growth(%) | -13.91 | 8.06 | -6.71 | -2.01 | 7.01 | 20.4 | -13.76 | 22.11 | 119.44 | 8.81 | -23.76 |
| EBIT Growth(%) | -63.15 | 7 | -114.88 | 1174.35 | 12.06 | 26.82 | -33.71 | 179.4 | 263.14 | 3.2 | -67.43 |
| PAT Growth(%) | -126.22 | -41.9 | -279.77 | 140.79 | 6.68 | 67.98 | -77.66 | 1373.43 | 317.47 | 3.02 | -77.67 |
| EPS Growth(%) | -126.22 | -41.83 | -280.02 | 140.78 | 6.72 | 67.99 | -77.62 | 1370.51 | 317.52 | 3.02 | -77.67 |
| Debt/Equity(x) | 0.52 | 0.37 | 0.55 | 0.56 | 0.73 | 0.6 | 0.57 | 0.47 | 0.23 | 0.33 | 0.37 |
| Current Ratio(x) | 1.67 | 1.89 | 1.67 | 1.84 | 1.6 | 1.33 | 1.33 | 1.39 | 1.67 | 1.85 | 1.94 |
| Quick Ratio(x) | 0.76 | 1.06 | 0.9 | 1.16 | 1.03 | 0.91 | 0.91 | 1.07 | 1.21 | 1.15 | 1.15 |
| Interest Cover(x) | 0.71 | 0.87 | -0.12 | 1.58 | 1.79 | 1.94 | 1.37 | 4.62 | 16.62 | 11.25 | 2.71 |
| Total Debt/Mcap(x) | 0 | 0.35 | 0.77 | 0 | 0.84 | 0 | 0.77 | 0.42 | 0.06 | 0.08 | 0.23 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 24.25 | 24.25 | 24.25 | 24.25 | 24.25 | 24.25 | 24.25 | 25.8 | 31.7 | 36.44 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0.14 | 0.14 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 75.75 | 75.75 | 75.75 | 75.75 | 75.75 | 75.75 | 75.61 | 74.06 | 68.3 | 63.56 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.12 | 0.14 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.26 | 0.24 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.37 | 0.37 | 0.37 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -23% | +24% | +14% | +9% |
| Operating Profit CAGR | -67% | 0% | +15% | +7% |
| PAT CAGR | -67% | 0% | — | — |
| Share Price CAGR | -29% | -25% | +65% | +31% |
| ROE Average | +6% | +25% | +18% | +8% |
| ROCE Average | +9% | +30% | +22% | +13% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 24.25 | 24.25 | 24.25 | 24.25 | 24.25 | 24.25 | 24.25 | 25.8 | 31.7 | 36.44 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0.14 | 0.14 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 75.75 | 75.75 | 75.75 | 75.75 | 75.75 | 75.75 | 75.61 | 74.06 | 68.3 | 63.56 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.12 | 0.14 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.26 | 0.24 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.37 | 0.37 | 0.37 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.